eNoglow Chemical Exhaled Gas Analyzer

The WLD801 is a non-invasive analyzer that measures exhaled nitric oxide (FeNO) levels to assess airway inflammation in respiratory conditions such as asthma and allergic rhinitis. It provides rapid, objective diagnostic support for clinicians in pulmonology and allergy departments. The device delivers quantitative results with high sensitivity and specificity for patient management.

Portable breath analyzer for measuring fractional exhaled nitric oxide (FeNO) levels, used in clinical assessment of airway inflammation and asthma management. The device provides rapid, non-invasive diagnostic testing suitable for point-of-care and home-based monitoring applications.

A breath testing device designed for clinics, pharmacies, health screening centers, nursing homes, and community settings. It uses the same gas detection technology as hospital systems with interconnected diagnostic and treatment services, enabling hierarchical diagnosis and treatment of chronic respiratory diseases and cardiopulmonary health screening. It provides FeNO/CaNO/FeCO/FnNO testing for cough and asthma patients to optimize medication selection, reduce acute exacerbations and emergency hospitalization, and for susceptible populations for risk warning and disease prevention.

A home-use breath analyzer designed for patients with chronic respiratory diseases and susceptible populations, featuring a mobile application and detection diagnostic treatment service card. It offers FeNO/FnNO self-testing capabilities using hospital-grade gas detection technology with interconnected diagnostic services, enabling chronic respiratory disease patients to reduce acute exacerbations and emergency hospitalization, and susceptible populations to reduce disease development risk.

A multi-molecular, multi-site, multi-parameter breath analysis system for detecting inflammation and related conditions. The CA series includes multiple configurations (CA3478, CA3138, CA4458) that measure various exhaled gases including NO, CO, H2S, CH4, CO2, and O2 in different combinations. It supports online and offline sampling modes with quality control features, and is designed for respiratory, pediatric, ENT, surgical, radiology, and physical examination departments to diagnose conditions such as asthma, COPD, interstitial lung disease, lung cancer, chronic cough, allergic rhinitis, sinusitis, and perioperative pulmonary complications.

An advanced multi-molecular breath analysis system featuring variable flow rate measurements and AI olfactory diagnostics. The DA series (DA2123 and DA7349 models) measures multiple exhaled gases including NO, H2S, H2, CH4, CO, CO2, and O2 for comprehensive inflammation and microbiota assessment. It is designed for respiratory, digestive, allergy, and immunology departments for academic research and high-level clinical services, addressing conditions related to microbiota imbalance and inflammation-related diseases.

A breath analysis device designed for clinics, pharmacies, health check centers, nursing homes, and community settings using the same gas detection technology as hospital systems. The TM series performs FeNO/CaNO/FeCO/FnNO testing for respiratory chronic disease tiered diagnosis and heart-lung health screening, helping optimize drug selection and reduce acute exacerbations, emergency hospitalizations, and lung cancer risk.

A breath analysis device for multi-molecular, multi-site, multi-parameter testing of respiratory and digestive conditions with complications. The CA series includes inflammatory phenotyping breath testing with NO baseline plus CO and H2S optional configurations, supporting online standard, offline, and tidal breath modes. It features breath quality control with standard gas and self-calibration, and is applicable to respiratory, pediatric, otolaryngology, surgery, radiology, and health screening departments for conditions including asthma, COPD, interstitial lung disease, lung cancer, chronic cough, allergic rhinitis, sinusitis, nasal polyps, radiation pneumonitis, and perioperative pulmonary complications.

A breath analyzer designed for patients with chronic respiratory diseases and susceptible populations, equipped with a mobile application and detection diagnostic treatment service card. It uses the same gas detection technology as hospital systems with interconnected diagnostic and treatment services, providing FeNO/FnNO self-testing for chronic cough and asthma patients to reduce acute exacerbations and emergency hospitalization, and for susceptible populations to reduce disease onset risk and progression to chronic disease.

A multi-molecular breath analysis system that detects NO, H2S, H2, CH4, CO, CO2, and O2 for simultaneous assessment of intestinal inflammation and microbiota status. It features olfactory AI and multimodal diagnostic capabilities. The device is designed for use in gastroenterology, pediatrics, physical examinations, and allergy departments, and is indicated for conditions including irritable bowel syndrome, inflammatory bowel disease, colorectal cancer, Helicobacter pylori infection, functional dyspepsia, liver disease, and allergic rhinitis/asthma.

A home-use breath analyzer designed for chronic respiratory disease patients and susceptible populations, featuring mobile application integration and diagnostic service support. The NA series enables FeNO/FnNO self-testing for individual risk assessment and management, reducing the incidence of acute exacerbations and preventing the development of chronic respiratory diseases.

An advanced breath analysis device for multi-molecular, multi-parameter inflammation and bacterial microbiota testing. The DA series includes configurations such as DA2123 with variable flow rate multi-parameter testing and DA7349 with NO, H2S, H2, CH4, CO, CO2, and O2 for comprehensive inflammation and microbiota breath testing plus AI olfactory diagnosis. It is designed for respiratory, digestive, allergy, and immunology departments for academic research and clinical applications including allergic rhinitis, asthma, irritable bowel syndrome, inflammatory bowel disease, colorectal cancer, and gut-lung, gut-heart, gut-liver, and gut-brain axis dysbiosis conditions.